399 related articles for article (PubMed ID: 28499587)
1. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Oehrl S; Prakash H; Ebling A; Trenkler N; Wölbing P; Kunze A; Döbel T; Schmitz M; Enk A; Schäkel K
J Dermatol Sci; 2017 Aug; 87(2):110-115. PubMed ID: 28499587
[TBL] [Abstract][Full Text] [Related]
2. Controlling the pro-inflammatory function of 6-sulfo LacNAc (slan) dendritic cells with dimethylfumarate.
Oehrl S; Olaru F; Kunze A; Maas M; Pezer S; Schmitz M; Schäkel K
J Dermatol Sci; 2017 Sep; 87(3):278-284. PubMed ID: 28732748
[TBL] [Abstract][Full Text] [Related]
3. Reduction of inflammatory slan (6-sulfo LacNAc) dendritic cells in psoriatic skin of patients treated with etanercept.
Günther C; Blau K; Förster U; Viehweg A; Wozel G; Schäkel K
Exp Dermatol; 2013 Aug; 22(8):535-40. PubMed ID: 23879812
[TBL] [Abstract][Full Text] [Related]
4. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus.
Hänsel A; Günther C; Baran W; Bidier M; Lorenz HM; Schmitz M; Bachmann M; Döbel T; Enk AH; Schäkel K
J Autoimmun; 2013 Feb; 40():1-8. PubMed ID: 22890025
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
[TBL] [Abstract][Full Text] [Related]
6. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses.
Hänsel A; Günther C; Ingwersen J; Starke J; Schmitz M; Bachmann M; Meurer M; Rieber EP; Schäkel K
J Allergy Clin Immunol; 2011 Mar; 127(3):787-94.e1-9. PubMed ID: 21377044
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells.
Wehner R; Löbel B; Bornhäuser M; Schäkel K; Cartellieri M; Bachmann M; Rieber EP; Schmitz M
Int J Cancer; 2009 Jan; 124(2):358-66. PubMed ID: 18942710
[TBL] [Abstract][Full Text] [Related]
8. The phosphodiesterase 4 inhibitor roflumilast augments the Th17-promoting capability of dendritic cells by enhancing IL-23 production, and impairs their T cell stimulatory activity due to elevated IL-10.
Bros M; Montermann E; Cholaszczyńska A; Reske-Kunz AB
Int Immunopharmacol; 2016 Jun; 35():174-184. PubMed ID: 27070502
[TBL] [Abstract][Full Text] [Related]
9. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.
Schafer PH; Parton A; Gandhi AK; Capone L; Adams M; Wu L; Bartlett JB; Loveland MA; Gilhar A; Cheung YF; Baillie GS; Houslay MD; Man HW; Muller GW; Stirling DI
Br J Pharmacol; 2010 Feb; 159(4):842-55. PubMed ID: 20050849
[TBL] [Abstract][Full Text] [Related]
10. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages.
Brunner PM; Koszik F; Reininger B; Kalb ML; Bauer W; Stingl G
J Allergy Clin Immunol; 2013 Nov; 132(5):1184-1193.e8. PubMed ID: 23890755
[TBL] [Abstract][Full Text] [Related]
11. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
12. Human 6-sulfo LacNAc (slan) dendritic cells are a major population of dermal dendritic cells in steady state and inflammation.
Günther C; Starke J; Zimmermann N; Schäkel K
Clin Exp Dermatol; 2012 Mar; 37(2):169-76. PubMed ID: 22188261
[TBL] [Abstract][Full Text] [Related]
13. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
Perez-Aso M; Montesinos MC; Mediero A; Wilder T; Schafer PH; Cronstein B
Arthritis Res Ther; 2015 Sep; 17(1):249. PubMed ID: 26370839
[TBL] [Abstract][Full Text] [Related]
14. Pollen-derived low-molecular weight factors inhibit 6-sulfo LacNAc+ dendritic cells' capacity to induce T-helper type 1 responses.
Gilles S; Jacoby D; Blume C; Mueller MJ; Jakob T; Behrendt H; Schaekel K; Traidl-Hoffmann C
Clin Exp Allergy; 2010 Feb; 40(2):269-78. PubMed ID: 20210806
[TBL] [Abstract][Full Text] [Related]
15. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
[TBL] [Abstract][Full Text] [Related]
16. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
Schafer P
Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Pincelli C; Schafer PH; French LE; Augustin M; Krueger JG
J Drugs Dermatol; 2018 Aug; 17(8):835-840. PubMed ID: 30124722
[TBL] [Abstract][Full Text] [Related]
18. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
[TBL] [Abstract][Full Text] [Related]
19. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis.
Lovato P; Norsgaard H; Tokura Y; Røpke MA
J Dermatol Sci; 2016 Mar; 81(3):153-64. PubMed ID: 26794805
[TBL] [Abstract][Full Text] [Related]
20. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Schafer PH; Chen P; Fang L; Wang A; Chopra R
J Immunol Res; 2015; 2015():906349. PubMed ID: 25973439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
